Stockreport

MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference

MAIA Biotechnology, Inc.  (MAIA) 
PDF Updates from THIO-101 to include response rates and survival follow-up CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company [Read more]